Physician profile
Azita Simoni
NPI 1366418931
$39,015.43
in general payments reported to CMS, 2019-2025
37 companies · $6,376 in 2025
The $6,376 reported for 2025 was more than what 91% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,121 · 2020: $1,782 · 2021: $6,288 · 2022: $14K · 2023: $3,958 · 2024: $3,564 · 2025: $6,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $1,350 · Travel and Lodging: $20.34 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,518.15 |
| Consulting Fee | $1,350.00 |
| Travel and Lodging | $20.34 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $9,948.02 | 2019-2022 | |
| Medimetriks Pharmaceuticals, INC. | $5,756.52 | 2019-2025 | Neo-Synalar, Genadur, Clindacin Etz |
| Journey Medical Corporation | $3,461.24 | 2019-2025 | Emrosi |
| Incyte Corporation | $1,753.85 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $1,736.26 | 2019-2025 | Aklief, Nemluvio, Epsolay |
| Leo Pharma INC. | $1,637.86 | 2019-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,275.49 | 2019-2025 | Cabtreo, Jublia, Arazlo |
| Sun Pharmaceutical Industries INC. | $1,222.64 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Abbvie INC. | $1,143.14 | 2022-2025 | Skyrizi |
| Lilly USA, LLC | $1,100.88 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $1,063.63 | 2021-2025 | Otezla, Otezla |
| Genzyme Corporation | $1,015.54 | 2021-2025 | |
| Pfizer INC. | $923.09 | 2019-2025 | |
| Prugen, INC. Pharmaceuticals | $871.69 | 2019-2021 | |
| Almirall LLC | $871.45 | 2019-2025 | Klisyri, Seysara |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $795.52 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $571.80 | 2020-2025 | Dupixent |
| Biofrontera INC. | $472.16 | 2019 | |
| Arcutis Biotherapeutics, INC. | $408.95 | 2024-2025 | Zoryve |
| Janssen Biotech, INC. | $374.24 | 2019-2024 | Tremfya |
| Ucb, INC. | $371.40 | 2021-2025 | Bimzelx |
| Mayne Pharma Commercial LLC | $337.70 | 2019-2025 | |
| Organon LLC | $335.31 | 2025 | Vtama |
| Dermavant Sciences, INC. | $262.23 | 2022-2024 | Vtama |
| Vyne Pharmaceuticals INC. | $216.30 | 2020-2021 | |
| Botanix Sb INC | $191.28 | 2025 | Sofdra |
| Sanofi Pasteur INC. | $150.00 | 2020 | |
| Dermira, INC. | $145.36 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $124.54 | 2022-2023 | Sotyktu |
| Ani Pharmaceuticals, INC. | $95.35 | 2025 | Veregen |
| Sanofi-Aventis U.S. LLC | $84.63 | 2019-2021 | |
| Celgene Corporation | $83.39 | 2019 | |
| Sebela Pharmaceuticals INC. | $35.39 | 2022 | |
| Pierre Fabre Pharmaceuticals, INC. | $21.00 | 2019 | |
| Organogenesis INC. | $18.62 | 2024 | |
| Encore Dermatology INC. | $13.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azita Simoni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.